Literature DB >> 17935015

Application of the ICF in reduced speech intelligibility in dysarthria.

Allyson D Dykstra1, Mark E Hakel, Scott G Adams.   

Abstract

Regardless of the underlying neuromotor impairment, an almost universal consequence of dysarthria is a reduction in speech intelligibility. The purpose of this article is to examine critically and to discuss issues related directly to speech intelligibility in speakers with dysarthria. Reduced speech intelligibility resulting from dysarthria is examined using the World Health Organization's International Classification of Functioning, Disability and Health (ICF) conceptual framework. We propose that the ICF conceptual framework facilitates an awareness of the multidimensional nature of disablement. Furthermore, the ICF facilitates a broad understanding of the complex nature of dysarthria, ranging from the neuroanatomical and physiological substrates contributing to reduced speech intelligibility, to the effects of this type of communication disorder on an individual's functioning in society and beyond. Finally, a case example is presented that describes how the ICF can be applied to an individual with dysarthria and reduced speech intelligibility.

Entities:  

Mesh:

Year:  2007        PMID: 17935015     DOI: 10.1055/s-2007-986527

Source DB:  PubMed          Journal:  Semin Speech Lang        ISSN: 0734-0478            Impact factor:   1.761


  12 in total

1.  A qualitative study of interference with communicative participation across communication disorders in adults.

Authors:  Carolyn Baylor; Michael Burns; Tanya Eadie; Deanna Britton; Kathryn Yorkston
Journal:  Am J Speech Lang Pathol       Date:  2011-08-03       Impact factor: 2.408

2.  The Effect of SPEAK OUT! and The LOUD Crowd on Dysarthria Due to Parkinson's Disease.

Authors:  Alison Behrman; Jennifer Cody; Samantha Elandary; Peter Flom; Shilpa Chitnis
Journal:  Am J Speech Lang Pathol       Date:  2020-05-18       Impact factor: 2.408

3.  Separate and Combined Influence of Cognitive Impairment and Dysarthria on Functional Communication in Multiple Sclerosis.

Authors:  Lynda Feenaughty; Kris Tjaden; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  Am J Speech Lang Pathol       Date:  2018-08-06       Impact factor: 2.408

4.  Differentiating Typical From Atypical Speech Production in 5-Year-Old Children With Cerebral Palsy: A Comparative Analysis.

Authors:  Katherine C Hustad; Ashley Sakash; Aimee Teo Broman; Paul J Rathouz
Journal:  Am J Speech Lang Pathol       Date:  2019-07-15       Impact factor: 2.408

5.  Assessment of social function in four-year-old children with cerebral palsy.

Authors:  Emily McFadd; Katherine C Hustad
Journal:  Dev Neurorehabil       Date:  2013       Impact factor: 2.308

6.  Consonant Acoustics in Parkinson's Disease and Multiple Sclerosis: Comparison of Clear and Loud Speaking Conditions.

Authors:  Kris Tjaden; Vincent Martel-Sauvageau
Journal:  Am J Speech Lang Pathol       Date:  2017-06-22       Impact factor: 2.408

7.  Predicting Communicative Participation in Adults Across Communication Disorders.

Authors:  Jingyu Linna Jin; Carolyn Baylor; Kathryn Yorkston
Journal:  Am J Speech Lang Pathol       Date:  2021-03-03       Impact factor: 2.408

8.  From Speech Acoustics to Communicative Participation in Dysarthria: Toward a Causal Framework.

Authors:  Stephanie A Borrie; Camille J Wynn; Visar Berisha; Tyson S Barrett
Journal:  J Speech Lang Hear Res       Date:  2021-12-27       Impact factor: 2.674

9.  Effect of boost articulation therapy (BArT) on intelligibility in adults with dysarthria.

Authors:  Viviana Mendoza Ramos; Charlotte Paulyn; Leen Van den Steen; Maria E Hernandez-Diaz Huici; Marc De Bodt; Gwen Van Nuffelen
Journal:  Int J Lang Commun Disord       Date:  2021-01-23       Impact factor: 3.020

Review 10.  Obtaining Objective Clinical Measures During Telehealth Evaluations of Dysarthria.

Authors:  Jordanna S Sevitz; Brianna R Kiefer; Jessica E Huber; Michelle S Troche
Journal:  Am J Speech Lang Pathol       Date:  2021-03-10       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.